Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management
SCA Chen, D Marriott, EG Playford, Q Nguyen, D Ellis, W Meyer, TC Sorrell, M Slavin
Clinical Microbiology and Infection | ELSEVIER SCI LTD | Published : 2009
The study was supported by an educational grant from Pfizer Inc. M. Slavin, D. Marriott, D. Ellis, G. Playford and T. Sorrell are, or have been, on antifungal advisory boards of Gilead Sciences, Pfizer Australia, and Merck Sharp and Dohme, Australia; M. Slavin, D. Ellis, G. Playford and T. Sorrell are on the antifungal advisory board of Schering Plough; M. Slavin is on the antifungal advisory board of Bristol- Myers Squibb; T. Sorrell is on the advisory board of Pfizer Global; and S. Chen is on the antifungal advisory board of Gilead Sciences and Pfizer Australia. G. Playford and T. Sorrell have received financial support for research from Pfizer Australia and Merck Sharp and Dohme.